Filtered By:
Specialty: Pharmaceuticals
Condition: Heart Attack
This page shows you your search results in order of date.
Order by Relevance | Date
Total 165 results found since Jan 2013.
Antidepressant use in people with both physical health problems and depression
Many people with diseases such as cancer or diabetes or those who have had a heart attack or stroke also suffer from depression. How effective are antidepressants for these patients? And are they just as safe for these people as for those without physical health problems? Researchers from Charité - Universitätsmedizin Berlin and Aarhus University in Denmark have teamed up to investigate these questions.
Source: World Pharma News - September 8, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Roche and Alnylam report positive topline results from Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi therapeutic in development to treat hypertension in patients at high risk of cardiovascular disease
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placeboStudy met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conferenceBasel, 7 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase 2 study KARDIA-1 of zilebesiran, an investigational RNAi the...
Source: Roche Media News - September 7, 2023 Category: Pharmaceuticals Source Type: news
Many Heart Attack, Stroke Survivors Do Not Know Their Cholesterol Levels
WEDNESDAY, Aug. 30, 2023 -- Nearly half of heart attack and stroke survivors are unaware of their low-density lipoprotein (LDL) cholesterol levels, according to a survey released online by the American Heart Association (AHA).
The survey, conducted...
Source: Drugs.com - Pharma News - August 30, 2023 Category: Pharmaceuticals Source Type: news
ESC: Adverse Outcomes Increased With Suboptimal Adherence to Aspirin After MI
MONDAY, Aug. 28, 2023 -- Suboptimal adherence to aspirin after myocardial infarction (MI) is associated with an increased risk for recurrent MI, ischemic stroke, or death, according to a study presented at the European Society of Cardiology...
Source: Drugs.com - Pharma News - August 28, 2023 Category: Pharmaceuticals Source Type: news
P2Y ₁₂ Inhibitor Monotherapy Better Than Aspirin in Coronary Artery Disease
MONDAY, July 10, 2023 -- For patients with coronary artery disease (CAD), P2Y12 inhibitor monotherapy is associated with a lower risk for cardiovascular death, myocardial infarction, and stroke compared with aspirin monotherapy, according to a study...
Source: Drugs.com - Pharma News - July 10, 2023 Category: Pharmaceuticals Source Type: news
Uncontrolled Heart Risk Factors Common in Head, Neck Squamous Cell Cancer
THURSDAY, June 29, 2023 -- The burden of suboptimally controlled cardiovascular (CV) risk factors and incident risk of stroke and myocardial infarction (MI) are considerable in patients with head and neck squamous cell carcinoma (HNSCC), according...
Source: Drugs.com - Pharma News - June 29, 2023 Category: Pharmaceuticals Source Type: news
Women With Migraine Have Higher Risk for Heart Attack, Hemorrhagic Stroke
TUESDAY, June 13, 2023 -- The risk for ischemic stroke in individuals with migraine is similar for men and women, while the risk for myocardial infarction (MI) and hemorrhagic stroke is only higher in women with migraine, according to a study...
Source: Drugs.com - Pharma News - June 13, 2023 Category: Pharmaceuticals Source Type: news
Cancer Patients Who Continue Smoking After Diagnosis at Risk of CVD Events
FRIDAY, June 2, 2023 -- Cancer patients who continue smoking after their diagnosis have an increased risk for heart attack, stroke, or death due to cardiovascular disease (CVD) compared with nonsmokers, according to a study published online June 1...
Source: Drugs.com - Pharma News - June 2, 2023 Category: Pharmaceuticals Source Type: news
CVD Events Increased for Cancer Patients Who Continue Smoking After Diagnosis
FRIDAY, June 2, 2023 -- Cancer patients who continue smoking after their diagnosis have an increased risk for heart attack, stroke, or death due to cardiovascular disease (CVD) compared with nonsmokers, according to a study published online June 1...
Source: Drugs.com - Pharma News - June 2, 2023 Category: Pharmaceuticals Source Type: news
New calculator demonstrates how improved adherence to anti-diabetic medicines can benefit people in Medicaid
Diabetes is a scary diagnosis for anyone. When people with the disease struggle to manage their blood sugar levels, they can experience significant, life-threatening and costly complications such as heart attack, stroke, kidney failure, amputation and blindness. Fortunately, diabetescan be well-managed with comprehensive access to health care services, including medicines.
Source: The Catalyst - May 25, 2023 Category: Pharmaceuticals Authors: Reid Porter Tags: Diabetes Adherence Medicaid Source Type: news
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
RARITAN, NJ, May 25, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that all three prospective indications for milvexian, an investigational oral factor XIa (FXIa) inhibitor (being developed in collaboration with Bristol Myers Squibb), have now been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA). The designations cover all three indication-seeking studies within the Phase 3 Librexia development program (Librexia STROKE, Librexia ACS and Librexia AF), which are all dosing patients. The Librexia program is unrivaled as the most comprehensive FXIa clinical...
Source: Johnson and Johnson - May 25, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Risk for MI, Ischemic Stroke Increased for Younger Adults With Mental Disorders
TUESDAY, May 9, 2023 -- Younger adults with mental disorders have an increased risk for myocardial infarction (MI) and ischemic stroke (IS), according to a study published online April 28 in the European Journal of Preventive Cardiology.
Chan Soon...
Source: Drugs.com - Pharma News - May 9, 2023 Category: Pharmaceuticals Source Type: news
ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Cell Therapy Prevents Risk Of Heart Attack or Stroke: Study
A recent study searches for a permanent solution to repair the heart via stem cell therapy.
Source: Forbes.com Healthcare News - March 24, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
